Powered By
ESR1 mutations confer resistance to aromatase inhibitor (AI) therapy by enabling the estrogen receptor to remain active in the absence of estrogen, a state known as ligand-independent ER activation.
*
*
True
False
There is a 5x greater risk of disease progression within 3 months after the emergence of an ESR1 mutation during first-line aromatase inhibitor treatment.
*
*
True
False
In HR+/HER2- metastatic breast cancer, approximately what proportion of patients develop ESR1 mutations during the course of aromatase inhibitor treatment?
*
*
Up to 10% of patients
Approximately 15-20% of patients
Approximately 25-30% of patients
Up to 40% of patients
Circulating tumor DNA (ctDNA) testing is a blood-based approach that may detect resistance mutations, such as ESR1 mutations, earlier than standard imaging or tumor marker assessment in patients receiving first-line aromatase inhibitor therapy for HR+/HER2- metastatic breast cancer.
*
*
True
False
Compared to waiting for radiographic progression to switch endocrine therapy, proactive ESR1 mutation monitoring and early intervention during first-line CDK4/6 inhibitor-based therapy may offer which of the following potential advantages?
*
*
A longer window of effective first-line disease control
Preservation of quality of life by avoiding deterioration associated with progression to second-line therapy
Both of the above
Which of the following statements about routine ctDNA-based ESR1 mutation monitoring during first-line CDK4/6 inhibitor plus aromatase inhibitor therapy in HR+/HER2- metastatic breast cancer is NOT accurate?
*
*
ctDNA-based ESR1 mutation monitoring is a minimally invasive, blood-based approach that can be incorporated into routine first-line monitoring visits alongside standard imaging and tumor marker assessment
ESR1 mutations detected via ctDNA during first-line therapy represent a resistance signal specific to the aromatase inhibitor component, providing an opportunity to modify the endocrine therapy partner while preserving the CDK4/6 inhibitor backbone
Routine ctDNA-based ESR1 monitoring is already widely adopted in clinical practice, with the majority of eligible patients undergoing testing during first-line therapy
ESR1 mutations detected via ctDNA during first-line therapy may be identified up to 3–6 months before radiographic evidence of disease progression appears, providing a clinically meaningful window for proactive intervention
Source
*
*
*
*
*
That’s correct!
That’s incorrect.
The correct answer is:
Next question
Back
1/3
Next
Correct Answers
*
*
*
*
*